We are looking for innovative approaches to accelerate the development of therapeutics:
- Artificial intelligence/Machine learning (AI/ML)
- Synthesis and profiling automation
- Novel approaches to accelerate discovery and synthesis of new molecular entities
- Tissue targeting vectors for siRNA or Radioligand therapy (RLT)
- Preclinical small molecule leads for innovative therapies
Avi Spier
- Novel approaches/platforms that leverage AI/ML and wet lab capabilities for challenging and multi-specific antibody discovery.
- Targeted delivery and selective tropism to key tissues/cell types
- Biodistribution, intracellular trafficking and stability assessment of Adeno-associated virus (AAV), Radioligand therapeutics (RLTs), and targeted siRNA conjugates
Gianfranco de Pascale
- Targeted delivery approaches for RNA therapeutics to extra-hepatic tissues/cell types
- Innovative siRNA chemistry platforms
- In vivo/In vitro platforms to identify and validate siRNA targets
Gianfranco de Pascale
- Discovery of new RLT binders (“vectors”)
- Differentiated RLT assets that complement current pipeline and disease focus with novel isotopes, chelators or vectors for tumor specific RLT delivery
- Explore various combination approaches which are synergistic with RLTs
